Diabetes Islet Preservation Immune Treatment

NCT02586831 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study withdrawn prior to enrollment due to funding issues

Conditions

Diabetes Mellitus, Type 1
Hypoglycemia
Autoimmune Diseases
Diabetes Mellitus

Interventions

DRUG: Anti-Thymocyte Globulin (ATG)
DRUG: Interleukin 2
DRUG: Exenatide
DRUG: Adalimumab
OTHER: ATG Placebo
OTHER: IL-2 Placebo
OTHER: Adalimumab Placebo
OTHER: Exenatide Placebo

Sponsor

Camillo Ricordi and Jay Skyler

Collaborators

[object Object]